// App-Quantinova.ai

e14541 : Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors.

Researchers

Presenter

  • Marc Oliver Salzberg

Principal Investigators

  • Pierre Triozzi

  • Mitra Kooshki

  • Angela Tatiana Alistar

  • Rhonda Lynn Bitting

  • Joyce Fenstermaker

  • Guenther Lametschwandtner

  • Hans Loibner

Medical Centers

  • Sevilon, Marietta, GA

  • Wake Forest University, Winston-Salem, NC

  • Comprehensive Cancer Center Wake Forest University, Winston-Salem, NC

  • Wake Forest School of Medicine, Winston-Salem, NC

  • Wake Forest University, Hillsborough, NC

  • Apeiron Biologics AG, Vienna, Austria

  • Apeiron Biologics AG, Vienna, Austria

Locations

  • United States

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • APN-401

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02166255

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved